Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results